🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Background: * Flutamide is an approved drug for prostate cancer that block...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Start Date
2007-02-23
Trial ID
NCT00450463
Treatments Being Tested
This study will test the ability of an experimental vaccine to increase the...
Status
Completed
Location
National Cancer Institute (NCI), 9000 Rockville Pike
Start Date
2000-06-13
Trial ID
NCT00005916
Background: " Adenocarcinoma of the prostate is the most common cancer dia...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Start Date
2003-05-22
Trial ID
NCT00060528
Vaccines made from a gene-modified virus may help the body build an effecti...
Status
Completed
Location
Baptist Cancer Institute
Start Date
2006-02
Trial ID
NCT00108732
This randomized phase II trial studies how well docetaxel and prednisone wi...
Status
Terminated
Location
Mayo Clinic in Florida
Start Date
2010-08
Trial ID
NCT01145508
RATIONALE: Vaccines may make the body build an immune response to kill tumo...
Status
Completed
Location
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Start Date
2002-08
Trial ID
NCT00045227
Background: * Pox viral vectors can induce a PSA-specific T-cell responses...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Start Date
2004-11-01
Trial ID
NCT00096551
RATIONALE: Vaccines made from prostate cancer cells may make the body build...
Status
Completed
Location
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Start Date
2000-06
Trial ID
NCT00020254
Randomized phase II trial to determine the effectiveness of vaccine therapy...
Status
Terminated
Location
Dana-Farber Cancer Institute
Start Date
2000-01
Trial ID
NCT00005039